Brought to you by 
Swedish Oprhan Biovitrum to sell Cometriq in the EU for Exelixis; rights transition to new partner
01 Mar 2016
Executive Summary
Exelixis Inc. (oncology) has chosen Swedish Orphan Biovitrum AB (Sobi; rare disease drugs) to exclusively sell Cometriq (cabozantinib) in the European Union for metastatic medullary thyroid cancer (MTC). The term of the deal is three years.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Swedish Oprhan Biovitrum to sell Cometriq in the EU for Exelixis; rights transition to new partner
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice